NNNN Stock Chart & Stats
$22.59
--
Market closed
$22.59
--
Day’s Range― - ―
52-Week Range$8.30 - $54.95
Previous CloseN/A
VolumeN/A
Average Volume (3M)46.29K
Market Cap
$1.42B
Enterprise Value$688.35M
Total Cash (Recent Filing)$11.90M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)51.2
Beta1.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding43,891,200
10 Day Avg. Volume34,289
30 Day Avg. Volume46,292
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)43.77
Price to Sales (P/S)152.63
P/FCF Ratio-195.84
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue101.70
Enterprise Value/Gross Profit124.79
Enterprise Value/Ebitda245.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NNNN FAQ
What was Anbio Biotechnology Class A’s price range in the past 12 months?
Anbio Biotechnology Class A lowest stock price was $8.30 and its highest was $54.95 in the past 12 months.
What is Anbio Biotechnology Class A’s market cap?
Anbio Biotechnology Class A’s market cap is $1.42B.
When is Anbio Biotechnology Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anbio Biotechnology Class A’s earnings last quarter?
Currently, no data Available
Is Anbio Biotechnology Class A overvalued?
According to Wall Street analysts Anbio Biotechnology Class A’s price is currently Overvalued.
Does Anbio Biotechnology Class A pay dividends?
Anbio Biotechnology Class A does not currently pay dividends.
What is Anbio Biotechnology Class A’s EPS estimate?
Anbio Biotechnology Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anbio Biotechnology Class A have?
Anbio Biotechnology Class A has 43,891,200 shares outstanding.
What happened to Anbio Biotechnology Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anbio Biotechnology Class A?
Currently, no hedge funds are holding shares in NNNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anbio Biotechnology Class A Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
NNNN Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
81.28%
Trailing 12-Months
Company Description
Anbio Biotechnology Class A
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Technical Analysis
Merit Medical Systems
―
Repligen
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
― Other Institutional Investors
99.94% Public Companies and
Individual Investors









